Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUBJQ3)

DTT Name Neural cell adhesion molecule (NCAM)
Gene Name NCAM
DTT Type
Clinical trial target
 [1]
BioChemical Class
Immunoglobulin
UniProt ID
NOUNIPROTAC
TTD ID
T47165
KEGG Pathway
Cell adhesion molecules (CAMs) (hsa04514 )
Prion diseases (hsa05020 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IMGN901 DMIUC3M Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
FGLL DMY61GX Alzheimer disease 8A20 Phase 1 [2]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ERIC-1 DM08XS2 Solid tumour/cancer 2A00-2F9Z Terminated [3]
------------------------------------------------------------------------------------

References

1 Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66.
2 An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.
3 Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8.